Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?
Brigham and Women's Hospital, Boston (United States of America)
38
presentations
0
follower
6
more
presentations
in this session
Improvement of LDL-cholesterol goal attainment in high-risk patients in Europe and Middle East between 2008/09 and 2013/14 - Results of DYSIS and DYSIS II CHD
Do we reach the LDL-c goals in Familial hypercholesterolemiapatients under Eighteen Years Old? SAFEHEART (Spanish Familial Hypercholesterolemia Longitudinal Cohort Study) follow-up study
Still high prevalence of persistent lipid abnormalities among patients with ACS or stable CHD despite chronic statin therapy in 2014: results of DYSIS II ACS and CHD